Idiopathic Chronic Inflammatory Bowel DiseaseEPICODENCT02193464
Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk
An observational study of Idiopathic Chronic Inflammatory Bowel Disease, run by Kyungpook National University Hospital at 1 site in South Korea.
Trial summary
The purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of Korea. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Idiopathic Chronic Inflammatory Bowel Disease
- How many people
- 100 participants
- Where
- 1 siteSouth Korea
- Study dates
- Sep 2014to Dec 2026
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients with inflammatory bowel disease from primary, secondary, and tertiary hospital in Daegu-Gyeongbuk province of Korea.
Who may be able to join
- Clinical diagnosis of inflammatory bowel disease including Crohn's disease and ulcerative colitis
- Followed up for at least 6 months for the correct diagnosis
Who cannot join
- Patients who do not live in Daegu-Gyeongbuk province
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Keimyung University Dongsan Medical Center
Daegu, 700-712
Eun Soo Kim, MD, PhD, dandy813@hanmail.net
Eun Soo Kim, MD, PhD
About this study
Official title: Observational Study Using Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk, Southeastern Area of Korea
The purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of Korea.
- Keywords
- inflammatory bowel disease, registry, incidence, Korea
- Medical subject headings
- Inflammatory Bowel Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| inflammatory bowel disease | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
All newly diagnosed cases
In one year, all inflammatory bowel disease including Crohn's disease and ulcerative colitis which is newly diagnosed in Daegu-Gyeongbuk province of Korea is recorded.
Measured: one year
Secondary outcomes (1)
All operation cases
For one year, all patients who have surgical managements for IBD are counted.
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2014 (estimated)
- Study startSep 2014
- Primary completionDec 2025 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Idiopathic Chronic Inflammatory Bowel DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Kyungpook National University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Yeungnam University Hospital, Daegu Catholic University Medical Center, DongGuk University
- Responsible party
- Principal investigator, Eun Soo Kim, MD, PhD, Kyungpook National University Hospital
- Investigators
- Eun Soo Kim, MD, PhD, Principal investigator, Keimyung University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02193464
- Sponsor's protocol ID
- EPICODE
- Acronym
- EPICODE
- Status last verified
- Jan 2021
- First submitted
- 16 Jul 2014
- Last updated
- 12 Jan 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study Using Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk, Southeastern Area of Korea
- ClinicalTrials.gov ID
- NCT02193464
- Acronym / sponsor ID
- EPICODE / EPICODE
- Keywords
- inflammatory bowel disease, registry, incidence, Korea
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Kyungpook National University HospitalUniversity, hospital or other
- Collaborators
- Yeungnam University Hospital, Daegu Catholic University Medical Center, DongGuk University
- Study start
- Sep 2014 (actual)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 17 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of Korea.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| inflammatory bowel disease | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with inflammatory bowel disease from primary, secondary, and tertiary hospital in Daegu-Gyeongbuk province of Korea.
Key inclusion criteria (2 listed)
- Clinical diagnosis of inflammatory bowel disease including Crohn's disease and ulcerative colitis
- Followed up for at least 6 months for the correct diagnosis
Key exclusion criteria (1 listed)
- Patients who do not live in Daegu-Gyeongbuk province
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
All newly diagnosed cases
Time frame: one year
In one year, all inflammatory bowel disease including Crohn's disease and ulcerative colitis which is newly diagnosed in Daegu-Gyeongbuk province of Korea is recorded.
1 secondary outcome
All operation cases
Time frame: one year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2021.
Related trials for Idiopathic Chronic Inflammatory Bowel Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
Recruiting
Effect of Mediterranean Diet in Inflammatory Bowel Disease
Inflammatory Bowel Disease
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
RecruitingObservational study
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eun Soo Kim, MD, PhD principal investigator
Keimyung University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Idiopathic Chronic Inflammatory Bowel Disease, run by Kyungpook National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eun Soo Kim, MD. PhD (+82-53-250-7088, dandy813@hanmail.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All newly diagnosed cases (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2021.